State Street’s Nuvectis Pharma NVCT Stock Holding History

State Street’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.29M	Buy	166,516 +11,850	+8%	+$102K	﹤0.01%	3429
2025 Q4	$1.17M	Buy	154,666 +17,950	+13%	+$117K	﹤0.01%	3490
2025 Q3	$823K	Buy	136,716 +23,137	+20%	+$159K	﹤0.01%	3551
2025 Q2	$848K	Buy	113,579 +85,829	+309%	+$778K	﹤0.01%	3519
2025 Q1	$271K	Buy	27,750 +5,750	+26%	+$41.4K	﹤0.01%	3753
2024 Q4	$119K	Buy	22,000 +6,700	+44%	+$42K	﹤0.01%	3960
2024 Q3	$96.2K	Hold	15,300	–	–	﹤0.01%	3985
2024 Q2	$96.8K	Sell	15,300 -114,079	-88%	-$775K	﹤0.01%	4022
2024 Q1	$1.06M	Buy	129,379 +11,100	+9%	+$94.4K	﹤0.01%	3457
2023 Q4	$986K	Buy	118,279 +10,157	+9%	+$90.6K	﹤0.01%	3484
2023 Q3	$1.39M	Buy	108,122 +2,882	+3%	+$41.8K	﹤0.01%	3445
2023 Q2	$1.68M	Buy	105,240 +91,840	+685%	+$1.47M	﹤0.01%	3465
2023 Q1	$176K	Buy	13,400 +1,700	+15%	+$17.2K	﹤0.01%	4123
2022 Q4	$87.9K	Hold	11,700	–	–	﹤0.01%	4408
2022 Q3	$83K	Hold	11,700	–	–	﹤0.01%	4528
2022 Q2	$131K	Buy	+11,700	New	+$145K	﹤0.01%	4395

Other funds holding NVCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street's NVCT Position: Q1 2026 in Review

State Street increased its Nuvectis Pharma (NVCT) stake by 7.7% in Q1 2026, buying an estimated $102K and bringing the position to 166,516 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #3429.

State Street first reported a position in NVCT in Q2 2022 and has held it in 16 quarters since. The position peaked at $1.68M in Q2 2023. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

State Street held 166,516 shares of Nuvectis Pharma worth $1.29M as of Q1 2026.
State Street bought 11,850 Nuvectis Pharma shares in Q1 2026, an estimated $102K.
Nuvectis Pharma made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3429 holding.
State Street first reported a position in Nuvectis Pharma in Q2 2022 and has held it in 16 quarters since.
State Street's Nuvectis Pharma position peaked at $1.68M in Q2 2023.
62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.